(Q43247044)

17 November 2017

1 reference

title

Lenalidomide in multiple myeloma (English)

1 reference

17 November 2017

Bhawna Sirohi

1

1 reference

17 November 2017

Ray Powles

series ordinal

2

1 reference

17 November 2017

publication date

1 November 2009

1 reference

Expert Review of Anticancer Therapy

17 November 2017

published in

1 reference

17 November 2017

volume

9

1 reference

17 November 2017

issue

11

1 reference

17 November 2017

page(s)

1559-1570

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

The evolving background for high-dose treatment for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Treatment of plasma cell dyscrasias with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Genetics and cytogenetics of multiple myeloma: a workshop report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide in myelodysplastic syndrome and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Epidemiology and outcomes research for MGUS, myeloma and amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.123

21 January 2018

Identifiers

DOI

10.1586/ERA.09.123

1 reference

17 November 2017

1 reference